Novartis Opens Call on Remibrutinib REMODEL Trial in MS
Novartis held a conference call on October 23, 2026, to discuss REMODEL trial results for remibrutinib in relapsing multiple sclerosis. Speakers included Novartis neuroscience development head Nazem Atassi and U.S. president Victor Bulto, alongside Professor Heinz Wiendl. However, the provided article excerpt contains only the call’s opening remarks and does not report trial outcomes, efficacy figures, safety findings or company guidance. No conclusions about remibrutinib’s clinical performance can be drawn from this excerpt.
Neutral
The excerpt concerns Novartis and remibrutinib, a multiple sclerosis drug candidate, rather than cryptocurrencies or blockchain projects. It provides no clinical results or other information that would directly affect crypto trading, market liquidity or stability. Any short-term crypto response is therefore likely to be negligible. Broader biotech developments can sometimes influence general investor sentiment, but this excerpt lacks the substantive trial data that might move Novartis shares or affect risk appetite. The long-term impact on crypto markets is also expected to be minimal unless later developments have a wider effect on financial markets.